ProQR Therapeutics NV (MEX:PRQRN) Net Margin %: -658.29% (As of Mar. 2026)

What is ProQR Therapeutics NV Net Margin %?

ProQR Therapeutics NV MEX:PRQRN 44 Net Margin % is -658.29% as of Mar. 2026. GuruFocus rates MEX:PRQRN with a GF Score™ of 44/100 and a GF Value™ of MXN40.07. The stock has 5 warning signs investors should review. Among 947 Biotechnology companies, ProQR Therapeutics NV ranks worse than 66.31% on this metric.

Net margin is calculated as Net Income divided by its Revenue. ProQR Therapeutics NV's Net Income for the three months ended in Mar. 2026 was MXN-279.0 Mil. ProQR Therapeutics NV's Revenue for the three months ended in Mar. 2026 was MXN42.4 Mil. Therefore, ProQR Therapeutics NV's net margin for the quarter that ended in Mar. 2026 was -658.29%.

The historical rank and industry rank for ProQR Therapeutics NV's Net Margin % or its related term are showing as below:

MEX:PRQRN' s Net Margin % Range Over the Past 10 Years
Min: -4551.26 Med: -431.64 Max: -146.85
Current: -338.45

MEX:PRQRN's Net Margin % is ranked worse than
66.31% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs MEX:PRQRN: -338.45

ProQR Therapeutics NV (MEX:PRQRN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

ProQR Therapeutics NV Net Margin % Related Terms

ProQR Therapeutics NV Net Margin % Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Net Margin % Chart

ProQR Therapeutics NV Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Net Margin %

Get a 7-Day Free Trial

-4,549.79

-1,792.55

-431.67

-146.86

-265.21

ProQR Therapeutics NV Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Net Margin %	Get a 7-Day Free Trial															-223.04	-319.07	-381.88	-190.27	-658.29

MEX:PRQRN vs GALT, HRTX, PLYX: Net Margin % Comparison

For the Biotechnology subindustry, ProQR Therapeutics NV's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProQR Therapeutics NV Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Net Margin % distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Net Margin % falls into.

Save Embed

44GF Score

ProQR Therapeutics NV MEX:PRQRN

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ProQR Therapeutics NV Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

ProQR Therapeutics NV's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-889.406	/	335.361
	=	-265.21 %

ProQR Therapeutics NV's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-278.996	/	42.382
	=	-658.29 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of -658.29% mean?

ProQR Therapeutics NV (MEX:PRQRN) has a Net Margin % of -658.29% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on ProQR Therapeutics NV and its competitors. According to the industry distribution chart, ProQR Therapeutics NV ranks #628 out of 947 companies in the Biotechnology industry, placing it in the top 66.3%.

Is ProQR Therapeutics NV's Net Margin % too high?

ProQR Therapeutics NV's current Net Margin % is -658.29%. Based on the distribution chart, ProQR Therapeutics NV ranks #628 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ProQR Therapeutics NV has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.

How does ProQR Therapeutics NV's Net Margin % compare to GALT and HRTX?

According to the Biotechnology industry distribution chart, ProQR Therapeutics NV ranks #628 out of 947 companies for Net Margin %. This places ProQR Therapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Net Margin % is -658.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ProQR Therapeutics NV stock overvalued right now?

ProQR Therapeutics NV (MEX:PRQRN) has a current Net Margin % of -658.29%. The stock's GF Value™ is MXN40.07, compared to a current price of MXN36.00 — trading 10.2% below its estimated fair value. The current Net Margin % is -658.29%. ProQR Therapeutics NV's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current Net Margin % is -658.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of MXN36.00 is trading 10.2% below its estimated GF Value™ of MXN40.07.

Key valuation signals for MEX:PRQRN:

Net Margin %: -658.29%
GF Value™: MXN40.07 vs. price of MXN36.00 (10.2% below fair value)
GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Industry Healthcare Biotechnology

Comparable Companies GALT HRTX PLYX ORMP SPRO PLX MENS NRXP OKUR MIST VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges PRQR:USA 0PQ:Germany

Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK

Website https://www.proqr.com

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

44GF Score

Get the complete analysis for MEX:PRQRN

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN36.00

Price

MXN40.07

GF Value

View MEX:PRQRN Analysis

See Net Margin % data for all stocks →